HK1039342A1 - 結締組織生長因子(ctgf)及使用的方法 - Google Patents

結締組織生長因子(ctgf)及使用的方法 Download PDF

Info

Publication number
HK1039342A1
HK1039342A1 HK02100878.5A HK02100878A HK1039342A1 HK 1039342 A1 HK1039342 A1 HK 1039342A1 HK 02100878 A HK02100878 A HK 02100878A HK 1039342 A1 HK1039342 A1 HK 1039342A1
Authority
HK
Hong Kong
Prior art keywords
ctgf
growth factor
connective tissue
tissue growth
methods
Prior art date
Application number
HK02100878.5A
Other languages
English (en)
Chinese (zh)
Inventor
Frederick Schmidt Brian
Leah Allen Margaret
Sverdrup Fran
F. Carmichael David
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Priority claimed from PCT/US1999/026189 external-priority patent/WO2000027868A2/en
Publication of HK1039342A1 publication Critical patent/HK1039342A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK02100878.5A 1998-11-06 1999-11-05 結締組織生長因子(ctgf)及使用的方法 HK1039342A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US292036 1981-08-11
US187478 1998-11-06
US09/187,478 US6348329B1 (en) 1998-11-06 1998-11-06 Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
US09/292,036 US6358741B1 (en) 1998-11-06 1999-04-14 Connective tissue growth factor (CTGF) and methods of use
PCT/US1999/026189 WO2000027868A2 (en) 1998-11-06 1999-11-05 Connective tissue growth factor (ctgf) and methods of use

Publications (1)

Publication Number Publication Date
HK1039342A1 true HK1039342A1 (zh) 2002-04-19

Family

ID=22689164

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100878.5A HK1039342A1 (zh) 1998-11-06 1999-11-05 結締組織生長因子(ctgf)及使用的方法

Country Status (4)

Country Link
US (3) US6348329B1 (https=)
JP (1) JP4698837B2 (https=)
KR (1) KR20010102943A (https=)
HK (1) HK1039342A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
DK1140969T3 (da) * 1998-12-14 2007-09-17 Univ Miami Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1925306A3 (en) 2002-04-30 2008-09-17 Alcon, Inc. Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2003102161A2 (en) * 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing & treating diabetes and insulin resistance
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
WO2005077413A1 (en) * 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
WO2008027288A2 (en) 2006-08-30 2008-03-06 The Trustees Of Columbia University In The City Of New York Treatment for craniosynostosis by growth factor delivery
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2448971A1 (en) 2009-07-02 2012-05-09 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
KR101697396B1 (ko) 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
US8802839B2 (en) 2011-07-15 2014-08-12 Fibrogen, Inc. Connective tissue growth factor antisense oligonucleotides
EP3386544B1 (en) 2015-12-10 2020-11-25 Fibrogen, Inc. Methods for treatment of motor neuron diseases
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
EP0566673A1 (en) 1990-12-21 1993-10-27 Creative Biomolecules, Inc. Biosynthetic pdgf antagonists
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
US5916756A (en) 1993-12-14 1999-06-29 University Of South Florida Assay of connective tissue growth factor for detection of cell proliferative disorders
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof

Also Published As

Publication number Publication date
US6348329B1 (en) 2002-02-19
US6358741B1 (en) 2002-03-19
JP4698837B2 (ja) 2011-06-08
KR20010102943A (ko) 2001-11-17
US20020115156A1 (en) 2002-08-22
JP2002529066A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
HK1039342A1 (zh) 結締組織生長因子(ctgf)及使用的方法
AU4119899A (en) System for treating the fundus of an eye
AU2002365380A1 (en) Implant, method of making the same and use thereof for the treating of bones defects
AU2091699A (en) Variable permeability bone implants, methods for their preparation and use
ZA979820B (en) Methods for draping surgical incision sites.
AU3865899A (en) Apparatus and methods for the penetration of tissue, and the creation of an opening therein
HUP0103133A3 (en) Implant for repair of animal-cartilage, method for making the implant and cartilaginous tissue
EP1031830B8 (fr) Système électrochimique pour la détermination d'un temps de coagulation du sang
AU1435497A (en) Impression system for an implant end protruding from the human tissue structure
ZA977524B (en) Process for the preparation of bone cements comprising active compound.
AU1025199A (en) Coated medical implants, method for producing them, and use of the same for preventing restenosis
AU2002307430A1 (en) Method and system for photodisruption of tissue of the eye
AU3031899A (en) Nanoparticles, method for producing nanoparticles and use of the same
HK1045816A1 (zh) 角质细胞生长因子-2制剂
AU4224599A (en) Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
WO2000027868A3 (en) Connective tissue growth factor (ctgf) and methods of use
AU2178000A (en) Co-factors for trophic factors, and methods of use thereof
HK1046238A1 (zh) Calcilytic化合物
AU2001244991A1 (en) Implant having attachment and hole-insert parts, and method for producing such an implant
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU6366299A (en) Surgical suture
AU2002235202A1 (en) Treatment of bone disorders by modulation of fgfr3
AU4107100A (en) Method of producing composites, composites and the use of such composites
AU3212099A (en) Method for increasing the permeability of horny human tissue
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung